The most important financial indicators for the company Gama Biotech Production Srl - Unique Identification Number 29027632:
sales in 2023 was
340.472
euro, registering a net profit of
48.267
euro and having an average number of
2
employees.
Firma isi desfasoara activitatea in domeniul Fabricarea articolelor din material plastic pentru constructii having the NACE code 2223.
The table presents the most important indicators of the company from the Profit and Loss Account for the last 10 years of activity. The data show the company's evolution during this period, highlighting any increases or potential decreases recorded.
In the last year of activity, the sales decreased by -16.7%, from 410.046 euro in the year 2022, to 340.472 euro in 2023.
The Net Profit decreased by -53.176 euro, from 101.752 euro in 2022, to 48.267 in the last year.
Financial Analysis Reports provide a clear and comprehensive view of a company's financial activity. In addition to presenting financial data, the reports analyze this data so that any user can understand whether the results are positive or less favorable. The Financial Rating provides an analysis based on the most important financial ratios, including liquidity, solvency, and profitability. Payment Limits represent the maximum amounts for which a company can offer goods or services on credit to its clients. The Probability of Insolvency presents the theoretical probability that a company may not be able to meet its financial obligations towards its creditors, i.e., suppliers and financial institutions.
Debts, Equity, Inventories, Receivables, Accounts, Assets -
Gama Biotech Production Srl - CUI 29027632
2014
2015
2016
2017
2018
2019
2020
2021
2022
2023
Fixed Assets
20.125
17.424
3.874
2.910
117.659
32.345
52.244
141.686
126.397
110.845
Current Assets
6.254
1.477
65.155
107.219
202.670
210.649
240.571
181.579
211.940
240.776
Inventories
1.824
0
37.404
23.139
6.162
39.409
45.398
53.416
57.027
54.802
Receivables
3.785
1.184
8.074
46.640
62.286
61.159
38.285
60.639
54.749
75.575
Cash
646
293
19.677
37.439
134.222
110.081
156.888
67.524
100.164
110.398
Shareholders Funds
-85.112
-93.280
-15.367
55.413
165.650
191.625
258.378
243.643
271.018
274.998
Social Capital
67
67
67
68
67
65
64
63
63
63
Debts
111.491
112.182
84.396
54.795
154.811
52.181
34.767
80.846
68.528
78.740
Income in Advance
0
0
0
0
0
0
0
0
0
0
Exchange rate - RON
4.9465
4.9315
4.9468
4.8371
4.7454
4.6535
4.5681
4.4908
4.445
4.4821
Main CAEN
"2223 - 2223"
CAEN Financial Year
2229
The table presents the company's Balance Sheet structure for the last 10 years. Current Assets recorded a value of
240.776 euro in 2023 which includes Inventories of
54.802 euro, Receivables of
75.575 euro and cash availability of
110.398 euro.
The company's Equity was valued at
274.998 euro, while total Liabilities amounted to
78.740 euro.
Equity increased by 4.802 euro, from 271.018 euro in 2022, to 274.998 in 2023.
Activate the Financial Reports subscription with unlimited access and check the evolution and current financial situation of any company.
Subscriptions Financial Reports
You can check the financial situation of the companies in relation to the industry of which it is a part, credit limits and the risk of insolvency and suspension of accounts.
Subscription cost is per user. You can pay simultaneously up to 10 users.
RisCo Subscriptions offer the greatest flexibility in choosing the best services according to the needs of each user. These are structured into categories based on the type of service desired, as well as on different service contract periods: monthly, semi-annually, and annually. Check out the subscription offer for the best choices!
Similar services represent services associated with companies that allow for a better analysis of clients and suppliers. Company Contacts help you get in touch with the desired companies. Sector Studies provide an overview of an industry, the most important competitors, and the geographical distribution of companies. Company Lists allow you to attract new clients, while Import-Export services give you access to companies engaged in such activities.
Comments - Gama Biotech Production Srl